Version 40.3 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of several new studies on disease-modifying treatments as well as an added remark to tociluzumab and sarilumab recommendations acknowledging the release of updated results from REMAP-CAP.
- Remdesivir – one new study comparing remdesivir to standard care in 832 patients with moderate-critical COVID-19 (Ader et al. DisCoVeRy Trial SSRN preprint);
- Anakinra – one new study comparing anakinra to placebo in 796 hospitalised patients with critical COVID-19 (Derde et al. (REMAP-CAP), medRxiv doi: 10.1101/2021.06.18.21259133);
- Imatinib NEW – one new study comparing imatinib with placebo in 400 hospitalised patients with symptomatic COVID-19 (Aman et al. Lancet doi: 10.1016/S2213-2600(21)00237-X);
- Proxalutimide NEW – three new studies comparing proxalutimide with placebo in 504 non-hospitalised (Cadegiani et al. Cureus doi:10.7759/cureus.13492; McCoy et al. Research Square doi: 10.21203/rs.3.rs-135303/v3) and 645 hospitalised patients (Cadegiani et al. medRxiv doi: 10.1101/2021.06.22.21259318).
These studies are currently under review and will be incorporated in a future version of the guidelines.